Nombre del producto:7-benzyl-2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine

IUPAC Name:7-benzyl-2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine

CAS:1059735-34-0
Fórmula molecular:C14H13Cl2N3
Pureza:97%
Número de catálogo:CM105615
Peso molecular:294.18

Unidad de embalaje Stock disponible Precio($) Cantidad
CM105615-25g in stock ƻƙƀ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :1059735-34-0
Fórmula molecular:C14H13Cl2N3
Punto de fusión:-
Código de sonrisas:ClC1=C2C(CN(CC3=CC=CC=C3)CC2)=NC(Cl)=N1
Densidad:
Número de catálogo:CM105615
Peso molecular:294.18
Punto de ebullición:
Nº Mdl:MFCD11846183
Almacenamiento:Cool,ventilated,dry

Category Infos

Column Infos

Adagrasib
Jan. 10, 2024, EC approves KRAZATI (adagrasib) as a targeted treatment option for patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.
Adagrasib is an orally available, potent, irreversible, small molecule inhibitor of KRAS G12C mutant isoform for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation. Adagrasib covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state, thereby preventing downstream signalling without affecting wild-type KRAS protein.

Related Products